“`html
Zolgensma, a groundbreaking gene therapy priced at £1.79 million, holds the title of the world’s priciest medication. It’s employed to combat muscular dystrophy.
This revolutionary treatment offered a lifeline to a British infant. One-year-old Edward, residing in Colchester, Essex, suffered from spinal muscular atrophy—a condition stemming from a deficiency in a protein crucial for muscle development.
Britain’s National Health Service generously provided Edward with Zolgensma in August, a decision that cost a monumental £1.79 million.
Edward’s mother, Megan Willis, expressed astonishment at her son’s remarkable progress. She recounted improvements exceeding her wildest expectations.
Willis shared that Edward can now effortlessly roll over and sit unaided. He’s also begun taking his initial steps with assistance, as reported by the BBC.
Overwhelmed with joy, Willis stated, “My greatest hope was for him to simply sit. Knowing that, I now believe he’ll have a truly extraordinary life.”
